AmplifiDx, Inc. Secures $1.38 M to Develop Groundbreaking Molecular Point-of-Care System for Infectious Disease
May 15, 2023
AmplifiDx Inc., an emerging player in Molecular Diagnostics, is proud to announce that it has been awarded $1.38 million in funding from the National Institutes of Health (NIH) through the Rapid Acceleration of Diagnostics (RADx®) Tech program. This award provides an opportunity for AmplifiDx to secure more funding if milestones are met.
The contract supports the development of the AmplifiDxTM DX-100, a compact and affordable instrument designed for point-of-care (POC) testing. It will be accompanied by the AmplifiDxTM RespiFast Assay, a nucleic acid amplification test (NAAT) for Covid-19, Flu A and B, and RSV directly from one nasal swab. The simplicity of design and workflow makes it a unique and invaluable tool for managing patients with infectious diseases at the doctor’s office.
The DX-100 stands out as a molecular POC device due to its unique combination of visual appeal, high performance, low cost, and ease of use. Engineered for fast total turnaround times with high sensitivity, it offers confidence in the results typically only found in laboratory PCR tests. With the DX-100, a clear result is delivered while the patient is still present at the doctor’s office. This enables quick treatment decisions, reduces loss to follow-up thereby reducing the spread of disease and healthcare cost at once.
"We are thrilled to receive this funding from the NIH RADx Tech program. Our lab scientists, engineers and technicians are now on fire to deliver this crucial assay on our breakthrough platform." said Nancy Schoenbrunner, CEO of AmplifiDx Inc. “We were very successful at developing our foundational technology for COVID-19 under a previous RADx Tech contract. The guidance and support of the wider network provided by NIH through the RADx program were key to our achievements. We believe through this continued partnership and with our innovative and accessible testing solutions, we’ll make a difference in people's lives for years to come. Let’s do this!"
This project has been funded in part with Federal funds from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health, Department of Health and Human Services, under Contract No. 75N92023D00001.
About AmplifiDx, Inc.
AmplifiDx, Inc. was founded in 2020 by industry veterans with decades of experience in breakthrough molecular diagnostic and point of care testing solutions to market. The company has plans for menu expansion with early detection and disease management tests for the benefit of both healthcare professionals and the communities they serve. With the support of this grant, AmplifiDx is taking an important step toward fulfilling this mission. For more information on AmplifiDx Inc. and its revolutionary point of care testing solutions, visit www.amplifidx.com.
